The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 12, 2024

Filed:

Jan. 19, 2022
Applicant:

Sinocelltech Ltd., Beijing, CN;

Inventors:

Liangzhi Xie, Beijing, CN;

Chunxia Luo, Beijing, CN;

Wei Zhang, Beijing, CN;

Xiaoyan Suo, Beijing, CN;

Lin Pang, Beijing, CN;

Ping Hu, Beijing, CN;

Assignee:

SINOCELLTECH LTD., Beijing, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/025 (2006.01); A61K 39/12 (2006.01); A61P 31/20 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/025 (2013.01); A61K 39/12 (2013.01); A61P 31/20 (2018.01); C12N 7/00 (2013.01); A61K 2039/5258 (2013.01); C12N 2710/20022 (2013.01); C12N 2710/20023 (2013.01); C12N 2710/20034 (2013.01);
Abstract

The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.


Find Patent Forward Citations

Loading…